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1. Introduction
The eye is generally considered an immunologically privileged 
organ, and several mechanisms have been postulated to explain 
this phenomenon (Streilein et al., 2002; Caspi, 2006; Vallochi et 
al., 2007; Benhar et al., 2012). These include sequestration of anti-
gens behind the blood–retinal barrier; lack of lymphatic drainage; 
absence of professional antigen-presenting cells; and the existence 
of an inherently bestowed immune-suppressive environment 
through the production of cytokines like transforming growth 
factor-β (Cousins et al., 1991; Hamrah and Dana, 2007; Forrester 
and Xu, 2012). Because of sequestration, ocular antigens are not 
expected to be recognized by the developing thymocytes, leading 
to their escape from central tolerance. However, this notion is in-
creasingly being challenged, following demonstration of the ex-
pression of various retinal antigens, like interphotoreceptor ret-
inoid-binding protein (IRBP), and soluble antigens within the 
thymus (Charukamnoetkanok et al., 1998;  Takase et al., 2005). 
Nonetheless, alterations in the amounts of protein expression can 
still affect thymic education of T cells, leading to their safe exit 
into the peripheral repertoires (Anderson et al., 2000;  Klein et 
al., 2000). In genetically susceptible individuals, such a pre-exist-
ing repertoire of self-reactive T cells can be activated to become 
pathogenic cells, as might occur in response to exposure to in-
fectious agents. This phenomenon may involve a combination of 
mechanisms, such as bystander activation, release of cryptic epi-
topes, epitope spreading and molecular mimicry (Miller et al., 
1997b; Oldstone, 2005; Fujinami et al., 2006).
Molecular mimicry is a natural phenomenon in which mi-
crobes carrying sequences identical to those found in self-antigens 
can lead to the generation of cross-reactive immune responses di-
rected against both foreign and self-antigens (Fujinami and Old-
stone, 1985; Fujinami et al., 2006). Several experimental examples 
provide a proof-of-concept that the microbial mimics can break self-
tolerance and induce autoimmunity (Miller et al., 1997b; Oldstone, 
2005; Fujinami et al., 2006). Conversely, pathogens that primarily 
affect the target organs can lead to secondary generation of autoim-
mune responses by epitope spreading, as shown with Theiler’s mu-
rine encephalomyelitis virus-induced demyelination model in SJL 
mice (Miller et al., 1997a; Olson et al., 2002). However, when a dis-
ease process involves both molecular mimicry and epitope spread-
ing, the former generally precedes the latter.
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Abstract
We report here identification of novel mimicry epitopes for interphotoreceptor retinoid-binding protein (IRBP) 201–216, a candi-
date ocular antigen that causes experimental autoimmune uveoretinitis (EAU) in A/J mice. One mimicry epitope from Ehrlichia ca-
nis (EHC), designated EHC 44–59, induced cross-reactive T cells for IRBP 201–216 capable of producing T helper (Th)1 and Th17 
cytokines, but failed to induce EAU in A/J mice. In addition, animals first primed with suboptimal doses of IRBP 201–216 and sub-
sequently immunized with EHC 44–59 did not develop EAU; rather, the mimicry epitope prevented the disease induced by IRBP 
201–216. However, alteration in the composition of EHC 44–59 by substituting alanine with valine at position 49, similar to the 
composition of IRBP 201–216, enabled the mimicry epitope to acquire uveitogenicity. The data provide new insights as to how mi-
crobes containing mimicry sequences for retinal antigens can prevent ocular inflammation by acting as naturally occurring altered 
peptide ligands.
Keywords: Autoimmunity, Experimental autoimmune uveoretinitis, Molecular mimicry, Interphotoreceptor retinoid-binding pro-
tein, Cross-reactive T cells
Abbreviations:7-AAD, 7-aminoactinomycin D; APL, altered peptide ligand; CFA, complete Freund’s adjuvant; CLIP, class-II associ-
ated invariant chain peptide; CLN, Clostridium novyi; cpm, counts per minute; CTR, Chlamydia trachomatis; DELFIA, dissociation-
enhanced lanthanide fluoroimmunoassay; EAU, experimental autoimmune uveoretinitis; EHC, Ehrlichia canis; HEC, hepatitis C vi-
rus; HEL, hen egg white lysozyme; IRBP, interphotoreceptor retinoid-binding protein; IL, interleukin; IC50, half maximal inhibitory 
concentration; IFN, interferon; LN, lymph nodes; LNC, lymph node cells; MHC, major histocompatibility complex; PAB, Paracoccid-
ioides brasiliensis; PMA, phorbol 12-myristate 13-acetate; PSP, Pseudomonas putida; PT, pertussis toxin; RNase, bovine ribonuclease; 
RT, room temperature; SA, streptavidin; TCR, T cell receptor; tet+, tetramer positive; TRC, Trypanosoma cruzi.
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Our studies involve IRBP 201–216-induced experimental auto-
immune uveoretinitis (EAU) in A/J mice. Using IRBP 201–216 as a 
putative ocular antigen (Namba et al., 1998; Agarwal et al., 2012), 
we searched for mimicry sequences from pathogens primarily af-
fecting the eyes, with an expectation that such microbes can serve 
as ideal candidates to delineate autoimmune events in the immune 
pathogenesis of eye diseases. This search resulted in the identifica-
tion of 48 novel sequences belonging to various classes of microbes. 
One of these mimicry epitopes, derived from Ehrlichia canis (EHC) 
and designated EHC 44–59, induces cross-reactive T cells for IRBP 
201–216 capable of producing inflammatory cytokines of T helper 
(Th)1 and Th17 subsets. Unexpectedly, EHC 44–59 failed to induce 
EAU; rather, it prevented the development of disease induced by 
IRBP 201–216, possibly by acting as a naturally occurring altered 
peptide ligand (APL).
2. Materials and methods
2.1. Mice
Six- to eight-week-old female, A/J mice carrying the H-2a al-
lele IAk at the major histocompatibility complex (MHC) class II lo-
cus were procured from Jackson Laboratory (Bar Harbor, ME). The 
animals were maintained in accordance with the animal protocol 
guidelines of the University of Nebraska-Lincoln, Lincoln, NE.
2.2. Identification of mimicry epitopes for IRBP 201–216
We used bovine IRBP 201–216 (ADKDVVVLTSSRTGGV) as 
a disease-inducing retinal antigen (Caspi, 2003), in which the pu-
tative MHC class II- and T cell receptor (TCR)-binding sites have 
been identified (Figure 1; Namba et al., 1998). Using this sequence, 
we performed pattern searches using the prosite scan of the Bio-
informatics Toolkit (http://toolkit.tuebingen.mpg.de/patsearch, 
Max-Planck Institute for Developmental Biology, Tuebingen, Ger-
many). The pattern used was XDXDXXXXXSXXXXXX (underlined: 
TCR-contact residue; bold: MHC-anchor residues; X: non-critical 
residues).
2.3. Peptide synthesis
Peptides synthesized commercially on 9-fluorenylmethyloxy-
carbonyl chemistry (Neopeptide, Cambridge, MA) include IRBP 
201–216; EHC 44–59, HDKDVAVLASSRLSNR; Pseudomonas pu-
tida (PSP) 46–61, ADADALVLTRERTRID; Trypanosoma cruzi (TRC) 
94–109, DDSDVVVLTSENVEKS; Clostridium novyi (CLN) 14–29, 
DDKDLTNLTSSRPLAA; Chlamydia trachomatis (CTR) 133–148, 
ADKDLLQLVSSRVSVF; hepatitis C virus (HEC) 192–207, PEP-
DVVVLTSMLTDPS; Paracoccidioides brasiliensis (PAB) 1–16, MDG-
DVLRETSSRLSGG; bovine ribonuclease (RNase) 43–56, VNT-
FVHESLADVQA; N-terminal biotinylated hen egg white lysozyme 
(HEL) 46–61, YNTDGSTDYGILQINSR; and three APLs, designated 
with subscript ‘AP’ and a number 1, 2 or 3: EHC 44–59AP1, HDKDV-
VVLASSRLSNR; EHC 44–59AP2, HDKDVAVLTSSRLSNR and EHC 
44–59AP3, HDKDVVVLTSSRLSNR. All peptides were HPLC-puri-
fied (> 90%), confirmed by mass spectroscopy and dissolved in ster-
ile 1 × PBS prior to use.
2.4. Immunization procedures
To measure recall responses, peptides were emulsified in com-
plete Freund’s adjuvant (CFA) and administered s.c. (50 μg/mouse) 
in the inguinal and sternal regions and foot-pads (Massilamany et 
al., 2011a, 2011b). For disease induction, peptides were emulsified 
in CFA supplemented with Mycobacterium tuberculosis H37RA ex-
tract (Difco Laboratories, Detroit, MI) to a final concentration of 
5 mg/ml, and the emulsions were administered at indicated doses 
s.c. in the inguinal and sternal regions and base of the tail. Addi-
tionally, pertussis toxin (PT; List Biological Laboratories, Camp-
bell, CA) was administered i.p. at indicated doses on day 0 and day 2 
postimmunization ( Silver et al., 1995; Namba et al., 1998).
2.5. T cell proliferation assay
Groups of A/J mice were immunized with the indicated pep-
tides, and at termination on day 10 or day 21, the animals were eu-
thanized, and the draining lymph nodes (LN) were harvested to 
prepare single cell suspensions (Massilamany et al., 2011b). Lymph 
node cells (LNC) were stimulated with the indicated peptides (0–
100 μg/ml) at a density of 5 × 106 cells/ml for two days in growth 
medium containing 1 × RPMI medium supplemented with 10% fe-
tal bovine serum, 1  mM sodium pyruvate, 4  mM l-glutamine, 1  × 
each of non-essential amino acids and vitamin mixture, and 100 U/
ml penicillin–streptomycin (Lonza, Walkersville, MD). Cultures 
were then pulsed with 1  μCi of tritiated 3[H] thymidine/well (MP 
Biomedicals, Santa Ana, CA); 16 h later, the proliferative responses 
were measured as counts per minute (cpm) using a Wallac liquid 
scintillation counter (PerkinElmer, Waltham, MA; Massilamany et 
al., 2011a; Gangaplara et al., 2012).
2.6. IAk-binding assay
To determine the affinities of peptides binding to IAk, we used 
soluble IAk molecules expressed in baculovirus as we have described 
previously (Massilamany et al., 2011a, 2011b). Briefly, IAk con-
structs representing the extracellular domains of IAk-α and IAk-β 
were designed, in which the sequence of class II-associated invari-
ant-chain peptide (CLIP) 88–102 (VSQMRMATPLLMRPM) was 
tethered into the N-terminus of the IAk-β construct, followed by in-
troduction of a thrombin cleavage site to facilitate the release of the 
CLIP peptide. Soluble IAk molecules were expressed in baculovirus 
using sf9 insect cells, purified on an anti-IAk affinity column (clone, 
10–2.16; BioXcell, West Lebanon, NH) and cleaved with thrombin 
to obtain empty IAk molecules (Day et al., 2003; Massilamany et al., 
2011b). Cocktails of individual reaction mixtures were prepared to 
include thrombin-cleaved IAk monomers (0.35 μg), competitor pep-
tides [IRBP 201–216 or EHC 44–59 (0.000005 μM to 50 μM)] or al-
Figure 1. Comparison of microbial peptide sequences with IRBP 201–216. 
The peptide sequence of IRBP 201–216 was compared with the mimicry epi-
topes derived from various microbes. IRBP, Interphotoreceptor retinoid-
binding protein; EHC, Ehrlichia canis; PSP, Pseudomonas putida; TRC, Try-
panosoma cruzi; CLN, Clostridium novyi; CTR, Chlamydia trachomatis; HEC, 
hepatitis C virus; PAB, Paracoccidoides brasiliensis. Putative TCR- and MHC-
binding residues are shown, respectively, with top and bottom arrows. Iden-
tical residues are underlined, and the numbers in parentheses indicate the 
percent sequence identities with IRBP 201–216.
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tered peptides of EHC 44–59 (0.00001 μM to 100 μM), and a con-
stant amount of biotinylated reference peptide, HEL 46–61 (1 μM), 
in a buffer containing 50 mM sodium phosphate pH 7.0, 100 mM 
sodium chloride, 1  mM EDTA, and 1  × protease inhibitor (Sigma-
Aldrich, St. Louis, MO; Hausmann et al., 1999; Massilamany et al., 
2011b). The mixtures were incubated at room temperature (RT) 
overnight. In parallel, anti-IAk (10 μg/ml) was coated onto 96-well 
white fluorescence plates (Nunc, Rochester, NY) in sodium phos-
phate buffer 0.2 M, pH 6.8 overnight. Plates were washed five times 
with 1 × wash buffer (PerkinElmer) and blocked with 2% casein for 
2 h at 37 °C. After washing, the reaction mixtures described above 
were added in duplicate for each peptide and incubated on a rocker 
at RT for 1 h and washed. Europium-labeled streptavidin (SA) was 
then added to a concentration of 1 μg/ml in dissociation-enhanced 
lanthanide fluoroimmunoassay (DELFIA) buffer, followed by DEL-
FIA-enhancement solution (PerkinElmer). Fluorescence intensities 
were measured at excitation/emission wavelengths of 340/615 nm 
using a Victor Multi Label Plate Reader (PerkinElmer). Concentra-
tions of competitor peptides that prevented 50% binding of the 
reference peptide (HEL 46–61) were taken as the half maximal in-
hibitory concentration (IC50) for each peptide (Hausmann et al., 
1999; Massilamany et al., 2011b).
2.7. Enumeration of the frequencies of antigen-specific  
CD4 T cells by MHC class II/IAk tetramer staining
To determine the frequency of antigen-specific cells, LNC were 
obtained from mice immunized with IRBP 201–216 or EHC 44–59, 
and the cells were stimulated with the indicated peptides (50  μg/
ml) for two days and maintained in growth medium containing in-
terleukin (IL)-2 (eBioscience, San Diego, CA; Advanced Biotechnol-
ogies, Columbia, MD). Viable lymphoblasts were harvested on day 5 
by Ficoll-Hypaque density gradient centrifugation, washed twice us-
ing 1 × PBS to remove antigens; the cultures then were maintained 
in growth medium containing IL-2. On day 9, cells were stained 
with IAk/tetramers, anti-CD4 (eBioscience), and 7-aminoactinomy-
cin D (7-AAD; Invitrogen, Carlsbad, CA) as we have previously de-
scribed (Massilamany et al., 2010, 2011a). After acquiring the cells 
by flow cytometry (FACSCalibur, BD Biosciences, San Diego, CA), 
percentages of tetramer positive (tet+) cells were determined in the 
live (7-AAD−) CD4+ subset using FlowJo software (Tree Star, Ash-
land, OR).
2.8. Intracellular cytokine staining
Groups of mice were immunized with the indicated peptides. 
At termination, draining LNs were harvested to prepare single-
cell suspensions. Cells were stimulated with the corresponding 
peptides (50  μg/ml) for two days and maintained in growth me-
dium containing IL-2. On day 5 poststimulation, viable lympho-
blasts were harvested by Ficoll-Hypaque density gradient centrif-
ugation and washed twice using 1  × PBS to remove antigen. Cells 
were then stimulated with phorbol 12-myristate-13 acetate (PMA, 
10 ng/ml) and ionomycin (150 ng/ml; Sigma-Aldrich) for five hours 
in the presence of 2 mM monensin (GolgiStop, BD Pharmingen, San 
Diego, CA; Gangaplara et al., 2012; Massilamany et al., 2009). Af-
ter staining with anti-CD4 and 7-AAD, cells were fixed, permeabi-
lized and stained with anti-cytokine antibodies along with their re-
spective isotype controls (eBioscience). The cells were then acquired 
by flow cytometry, and the frequencies of cytokine-producing cells 
were determined in the live (7-AAD−) CD4+ subset. The clones of cy-
tokine antibodies used were: IL-2 (JES6-5H4); interferon (IFN)-γ 
(XMG1.2); IL-4 (11B11); IL-10 (JES5-16E3); IL-17A (eBio 17B7); 
and IL-17 F (eBio 18F10) (all from eBioscience).
2.9. Histopathology
At termination, the animals were euthanized and eyes were har-
vested. The freshly enucleated eyes were fixed in Davidson’s stock 
solution containing 10% phosphate-buffered formalin and 90% eth-
anol (Fisher Scientific, Pittsburgh, PA), and the eyes were cross-sec-
tioned at a thickness of 5 μm and stained by hematoxylin and eo-
sin (H and E) staining (Silver et al., 1995; Namba et al., 1998). Eyes 
were evaluated for inflammation by counting the foci in both eyes 
corresponding to the corneal–scleral junction, iris, cornea, choroid 
and retina; the counts were then added. Based on the morphology 
of infiltrating cells, inflammation was classified as neutrophilic, 
lymphocytic or mixed.
Table 1. Peptide sequences that mimic IRBP 201–216.
Source Sequencea Identity (%)
IRBP 201–216 ADKDVVVLTSSRTGGV 
Bacteria
  Brevibacterium linens BL2 ADKDVKWLTRERTTGT 62.5
  Ehrlichia canis str. Jake HDKDVAVLASSRLSNR 56.25
  Catenulispora acidiphila DSM 44928 PDGDVVVLTSKDFEGL 56.25
  Shewanella halifaxensis HAW-EB4 ADIARKALTSSRTIIV 56.25
  Pyrococcus horikoshii OT3 ADLDVVIATSRRGVDV 56.25
  Clostridium novyi NT DDKDLTNLTSSRPLAA 50
  Chlamydia trachomatis 434/Bu ADKDLLQLVSSRVSVF 50
  Pseudomonas aeruginosa UCBPP-PA14 KDYDVVYATSSRLMTA 50
  Burkholderia phytofirmans PsJN ADVDVSPLTSERAMAL 50
  Vibrio parahaemolyticus 16 EDYDVVFATSSRLFTA 50
  Salmonella enterica subsp. KGADVVVLTSGQTENK 50 
    enterica serovar Typhi str. CT18 
  Metallosphaera sedula DSM 5348 CSVDVVVLTSSLIAKS 50
  Citrobacter koseri ATCC BAA-895 KGADVVVLTSGQTDNK 50
  Salmonella enterica subsp.   KGADVVVLTSGQTENK 50 
    enterica serovar Typhi str. E02-1180 
  Salmonella enterica subsp. enterica  KGADVVVLTSGQTENK 50 
      serovar Paratyphi C strain RKS4594 
  Citrobacter sp. 30_2 KGADVVVLTSGQTDNK 50
  Citrobacter youngae ATCC 29220 KGADVVVLTSGQTDNK 50
  Pseudomonas putida KT2440 ADADALVLTRERTRID 50
  Mycobacterium smegmatis str. MC2 155 ADGDDHRLTGSRTLVS 50
  Burkholderia pseudomallei 9 ADGAIGVLTLSRTQDP 50
  Helicobacter bilis ATCC 43879 RDKDAYNLISSRLKPI 43.75
  Pseudomonas syringae pv. syringae B728a PDVDVSLVTSERTHSM 43.75
  Rhodopseudomonas palustris TIE-1 ADPDVLRMTSLRAHDQ 43.75
  Rhodopseudomonas palustris HaA2 DARDVVVLTSRPAQLS 43.75
  Rhodococcus jostii RHA1 NIMDVVVLTSVLSCLN 43.75
  Cyanobium sp. PCC 7001 NHADVVVLTSPAQYPA 43.75
  Acidobacterium capsulatum ATCC 51196 EGSDVVVLTSDNPRSE 43.75
  Rhodococcus erythropolis PR4 NIMDVVVLTSVLSCLN 43.75
  Rhodococcus opacus B4 NIMDVVVLTSVLSCLN 43.75
  Kingella kingae ADADLSELTIERTAQG 43.75
Fungi
  Schizosaccharomyces japonicus yFS275 DDKDFSVLHSSRLRSM 50
  Paracoccidioides brasiliensis Pb18 MDGDVLRETSSRLSGG 50
  Aspergillus niger KDKDGNYLLSSRHFST 43.75
  Magnaporthe grisea 70-15 GDDDVFVDTSTRSPLP 43.75
  Sclerotinia sclerotiorum 1980 DDEDVEFFTSKRQRKV 43.75
  Malassezia globosa CBS 7966 LDVDVPIETSERTAFT 43.75
  Ajellomyces capsulatus NAm1 ADKDLNINKSSRPSKA 43.75
Algae
  Ostreococcus lucimarinus CCE9901 ADGKSVDLTISRTGED 56.25
  Chlamydomonas reinhardtii FDKDMQELTSSRRILD 50
  Phaeodactylum tricornutum CCAP 1055/1 ADEDAVGLTQRRTTTA 50
  Guillardia theta ADPELLKLTSDRTLFE 43.75
Protozoa
  Dictyostelium discoideum AX4 ADKKNSTLTSSRGNNK 50
  Trypanosoma cruzi strain CL Brener DDSDVVVLTSENVEKS 50
  Leishmania braziliensis ADKDDPLALSSRSPML 43.75 
    MHOM/BR/75/M2904
Viruses
  Hepatitis C virus PEPDVVVLTSMLTDPS 50
Helminths 
  Brugia malayi SDSDVEAATSSRKRKT 43.75
Others
  Strongylocentrotus purpuratus IDLDVVVLTSSGNDRR 56.25 
    (sea urchin)
  Trichoplax adhaerens (metazoan) EDKDNQLLASSRRFAQ 43.75
a. Identical residues are underlined.
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2.10. Statistics
Differences in T cell proliferative responses, IAk-binding affini-
ties and cytokine analysis were determined using Student’s t-test. 
p ≤ 0.05 values were considered significant. Stimulation indices in-
dicated as ‘fold increase’ were calculated using the following for-
mula: cpm values obtained in peptide-stimulated cultures / cpm val-
ues obtained in medium control.
3. Results
3.1. Identification of mimicry epitopes for IRBP 201–216
IRBP is recognized as one of the candidate retinal antigens in 
EAU pathogenesis (Agarwal et al., 2012), and we used IRBP 201–
216 to identify mimicry sequences for two reasons: 1) IRBP 201–
216 induces EAU in susceptible mouse strains like A/J mice by 
generating IRBP-reactive T cells (Caspi, 2003); and 2) its putative 
MHC class II (IAk)- and TCR-contact residues have been identified 
(Namba et al., 1998). While aspartic acid (Asp) at position 202 and 
serine (Ser) at 210 are predicted to anchor the IAk molecule, Asp at 
position 204 is supposedly a TCR-contact residue (Figure 1; Namba 
et al., 1998). In our search, we kept these residues constant, with 
an expectation that the mimicry epitopes bearing the critical MHC- 
and TCR-contact residues should be able to induce cross-reactive T 
cell responses for IRBP 201–216. This analysis led us to identify 48 
sequences – belonging to various microbes such as bacteria, viruses, 
fungi, algae, protozoa and helminths, including two marine organ-
isms – that show a similarity of 43.75 to 62.5% with IRBP 201–216 
(Table 1). We chose a panel of seven of these mimics from microbes 
that have been implicated in various eye diseases for further testing 
(Figure  1). All the epitopes, except the viral mimic HEC 192–207, 
contained both MHC- and TCR-contact residues, making them ideal 
candidates to test for their immunogenicity.
3.2. T cells sensitized with IRBP 201–216 and EHC 44–59  
cross-react with each peptide
Using T cell proliferation assay based on 3[H] thymidine incor-
poration, we first verified whether IRBP-reactive T cells can re-
spond to mimicry epitopes by cross-reactivity. Briefly, LNC were 
isolated from mice immunized with IRBP 201–216, and the re-
Figure 2. EHC 44–59 induces cross-reactive T cells for IRBP 201–216. A. T cell proliferation. Six- to eight-week-old female A/J mice were immunized with 
IRBP 201–216 or EHC 44–59 in CFA. After 10 days, mice were sacrificed, the draining LN were harvested and single-cell suspensions were prepared. LNC were 
stimulated with the indicated peptides for two days followed by pulsing with 3[H] thymidine. Proliferative responses were measured 16 h later as cpm. RNase 
43–56, control. Mean ± SEM values obtained from three individual experiments involving 3–4 mice in each are shown. B. IAk-binding. The reaction mixtures 
containing thrombin-cleaved IAk monomers (0.35 μg), competitor peptides (IRBP 201–216 or EHC 44–59: 0.000005 μM to 50 μM) and biotinylated HEL 46–
61 (1 μM) were individually prepared and added in duplicate to fluorescence plates coated with anti-IAk. After washing and addition of europium-labeled SA 
and DELFIA-enhancer, fluorescence intensities were measured at excitation/emission wavelengths of 340/615 nm, and IC50 values were then calculated. Rep-
resentative data sets (mean ± SEM values) from three to four individual experiments with two replicates in each are shown.
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call responses were tested by stimulating the cells with IRBP and 
its mimicry epitopes (Figure  1). Figure  2A (left panel) shows that 
IRBP 201–216-sensitized LNC responded to IRBP 201–216 dose de-
pendently as expected, and the response was specific because the 
cells did not respond to RNase 43–56 (control). Likewise, a pro-
portion of IRBP-reactive cells also reacted to EHC 44–59 (1.6-fold, 
p = 0.007) when compared with the medium controls. Under sim-
ilar conditions, the T cell responses for other mimics were found 
to be not more than one-fold (data not shown). Hence, we focused 
only on EHC 44–59 to determine its ability to induce cross-reactive 
T cells for IRBP 201–216. As indicated in Figure  2A (right panel), 
the animals immunized with EHC 44–59 showed strong prolifer-
ative responses to EHC 44–59, suggesting that the peptide is im-
munogenic. Similarly, a fraction of EHC 44–59-sensitized LNC also 
responded to IRBP 201–216 (2-fold). The data suggest that cross-re-
active T cells are induced by each peptide. Finally, we asked whether 
EHC 44–59 can bind MHC class II/IAk molecules by establishing 
IAk-binding assay (Massilamany et al., 2011b). Using HEL 46–61 as 
a reference epitope, we ascertained that the IAk-binding affinities of 
both IRBP 201–216 and EHC 44–59 were comparable (IC50 values: 
 
 
 
 
 
 
 
 
12.04  ±  2.14 vs. 15.52  ±  3.61  μM; Figure  2B). Thus, we identified 
EHC 44–59 as a candidate mimicry epitope for IRBP 201–216.
3.3. Cross-reactive T cell responses induced by IRBP 201–216 
and EHC 44–59 are antigen-specific
To determine the antigen specificity of CD4 T cell responses in-
duced by IRBP 201–216 and EHC 44–59, we created MHC class II/
IAk tetramers based on a peptide exchange reaction (Massilamany 
et al., 2011a). Briefly, soluble IAk monomers containing CLIP 88–
102 were initially expressed in the baculovirus, and after cleaving 
the CLIP peptide, empty IAk molecules were derived, into which 
IRBP 201–216, EHC 44–59 or RNase 43–56 (control) peptides were 
loaded exogenously. The IAk-peptide complexes were then multi-
merized to derive tetramers. Antigen-sensitized LNC cultures were 
derived from mice immunized with IRBP 201–216 or EHC 44–59, 
and the cells were stained with IAk/tetramers. As expected, CD4 
T cells sensitized with IRBP 201–216 bound to IRBP tetramers 
(1.42%; Figure  3, top left panel); some also bound to EHC tetra-
mers (0.52%; Figure 3, middle left panel). Similar results were ob-
tained when EHC 44–59-sensitized CD4 T cells were stained with 
EHC tetramers (3.06%; Figure 3, middle right panel) and IRBP tet-
ramers (0.40%; Figure 3, top right panel). The binding of IRBP 201–
216 or EHC 44–59 tetramers was specific, since the staining inten-
sities obtained with the control tetramers (RNase 43–56) were low 
(~ 0.15%; Figure 3, lower panels). The data suggest that the T cells 
sensitized with IRBP 201–216 or EHC 44–59 can cross-react with 
each epitope with specificity.
Figure 3. Cross-reactive T cells induced by IRBP 201–216 and EHC 44–59 
are antigen specific. Groups of A/J mice were immunized with IRBP 201–
216 or EHC 44–59 in CFA. Ten days later, animals were killed and LN were 
harvested to prepare single cell suspensions. LNC were stimulated with pep-
tides for two days, and the cells were maintained in growth medium con-
taining IL-2 for a week. Viable lymphoblasts were harvested on day 9 post-
stimulation and stained with IAk/tetramers, anti-CD4 and 7-AAD. After 
acquiring the cells by flow cytometry, tet+ cells were analyzed in the live (7-
AAD−) CD4 subset using FlowJo software. RNase 43–56, control. Represen-
tative flow cytometric dot plots from three individual experiments involving 
3 to 4 mice in each are shown.
Figure 4.  IRBP 201–216 and EHC 44–59 induce identical pattern of cyto-
kines. A. Intracellular cytokine staining. A/J mice were immunized with the 
indicated peptides in CFA. Ten days later, animals were killed and LN were 
harvested to prepare single cell suspensions. LNC were stimulated with pep-
tides for two days, and the cells were maintained in growth medium contain-
ing IL-2. Viable lymphoblasts were harvested on day 5 poststimulation and 
stimulated with PMA and ionomycin in the presence of GolgiStop for five 
hours. After fixation and permeabilization, cells were stained with a panel of 
antibodies for Th1, Th2 and Th17 cytokines, followed by staining with anti-
CD4 and 7-AAD. After acquiring the cells by flow cytometry, cytokine-posi-
tive cells were analyzed in the live (7-AAD−) CD4 subset. Mean ± SEM val-
ues derived from three individual experiments involving 3 to 4 mice in each 
are shown. B. Cytokine ELISA. Culture supernatants harvested from the 
above cultures on day 2 poststimulation were analyzed by cytokine ELISA. 
Mean ± SEM values representing three to four individual experiments with 
two duplicates for each are shown.
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3.4. T cells sensitized with IRBP 201–216 or EHC 44–59 produce 
comparable cytokines
One of the hallmarks of autoreactive T cells is their ability to pro-
duce cytokines of Th1 and Th17 phenotypes that favor autoimmu-
nity, including EAU (Damsker et al., 2010; Horai and Caspi, 2011). 
Therefore, we performed cytokine analysis by intracellular cytokine 
staining and ELISA for a panel of Th1 (IL-2 and IFN-γ), Th2 (IL-4 
and IL-10) and Th17 (IL-17A and IL-17F) cytokines. Enumeration of 
the frequencies of cytokine-producing CD4 T cells in LNC cultures 
specific to IRBP 201–216 or EHC 44–59 revealed that the cells capa-
ble of producing all of the cytokines tested were present (Figure 4). 
By analyzing the ratios between the frequencies of Th1-, Th17- and 
Th2-cytokine producing cells, we noted that a greater percentage of 
CD4 T cells was positive for Th1 and Th17 than for Th2 cytokines 
in cultures stimulated with both IRBP 201–216 (p ≤ 0.02) and EHC 
44–59 (Figure 4A). We verified these results by cytokine ELISA us-
ing culture supernatants, and the patterns were reproduced for both 
peptides (Figure 4B; p ≤ 0.03). The finding that EHC 44–59-respon-
sive cells produced cytokines comparable to those produced by IRBP 
201–216-responsive cells raised the possibility that EHC 44–59 may 
be able to induce EAU in immunized animals.
3.5. EHC 44–59 lacks the ability to induce uveoretinitis
To ascertain the disease-inducing ability of EHC 44–59, we 
first established a positive control system by optimizing the dose 
for IRBP 201–216 to induce EAU in immunized animals. Histo-
logically, the infiltrates were predominantly comprised of lympho-
cytes and a few neutrophils. Doses of IRBP 201–216 up to 50 μg/
animal induced comparable histologic EAU, and the inflamma-
tory foci tended to be found more in the corneal–scleral junction, 
iris and ciliary body than in the choroid, cornea and retina (mean 
foci ± SEM, 7.75 ± 2.97; Table 2; Figure 5A, B, and C). In contrast, 
none of the animals immunized with EHC 44–59 showed any evi-
dence of inflammation (Figure 5D and E). This negative disease phe-
notype could not be altered by increasing PT even up to 1000 ng/
animal (Namba et al., 1998;  Silver et al., 1999) nor by immuniz-
ing the animals twice (Massilamany et al., 2011b; data not shown). 
Thus, we concluded that EHC 44–59 can generate cross-reactive T 
cells for IRBP capable of producing Th1 and Th17 cytokines, but it 
lacks uveitogenicity.
3.6. EHC 44–59 prevents EAU induced with IRBP 201–216
We investigated whether the inability of EHC 44–59 to induce 
EAU may be due to low frequencies of IRBP-reactive T cells gener-
ated in immunized animals. To address this possibility, we first im-
munized groups of animals with a suboptimal dose (10 μg) of IRBP 
201–216; one group of animals was subsequently immunized with 
EHC 44–59 seven days later, and at termination on day 21, eyes were 
evaluated for histologic disease. While the animals immunized with 
IRBP 201–216 alone (5/13  =  38.5%) had inflammatory foci in the 
eyes [Figure  6A (i) and A (ii)], none of the IRBP 201–216-primed/
EHC 44–59-immunized animals (n  =  9) showed inflammation [Fig-
ure  6A (iii)]. To determine whether this lack of disease was due to 
Figure 5. EHC 44–59 failed to induce uveoretinitis in A/J mice. Six- to eight-week-old mice were immunized with IRBP 201–216 or EHC 44–59 (50 μg/mouse) in 
CFA. PT (100 ng/mouse), was administered intraperitoneally on days 0 and 2 postimmunization. At termination on day 21, the animals were euthanized, and eyes 
were collected for histological evaluation of inflammation. Note lymphocytic infiltrations in iris (A), corneal–scleral junction (B) and retina (C) in animals immu-
nized with IRBP 201–216 and absence of infiltrates in EHC 44–59-immunized animals (D and E) (arrows: infiltrates). Original magnification, × 40 (bar = 20 μm). 
Representative data from three to five individual experiments each involving 5 to 9 mice are shown.
Table 2. Histological EAU induced with IRBP 201–216 and EHC 44–59 in A/J mice.
                                                                                                        Number of foci (mean ± SEM)                                                                              Total foci  (mean ± SEM)
Peptide                     Dose (μg)     Incidence (%)       Corneal–scleral junction                Iris              Cornea          Choroid            Retina 
IRBP 201–216     50 9/20 (45) 2.6 ± 0.89 4.25 ±1.93 0.3 ± 0.22 0.45 ±0.28 0.15 ±0.15 7.75 ±2.97 
EHC 44–59      50 0/21 (0) 0 0 0 0  0 0
 100 0/6 (0) 0 0 0 0  0 0 
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competition between IRBP 201–216 and EHC 44–59 for binding to 
MHC molecules, we immunized IRBP 201–216-primed animals with 
a control peptide (RNase 43–56). In this setting, we did observe in-
filtrates [2/4 = 50%; Figure 6A (iv)], suggesting that competition for 
MHC between peptides would not have accounted for lack of disease 
in animals immunized with IRBP and EHC peptides.
We next confirmed that the lack of EAU induction is not due 
to the absence of IRBP-reactive T cells. As shown in Figure 6B (left 
panel), the animals primed with IRBP 201–216 showed good pro-
liferative responses to IRBP 201–216 (4.93-fold, p  =  6.56E−  06) 
as compared to those in the medium controls, but the response to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EHC 44–59 was low (1.84-fold, p  =  0.0033). In contrast, LNC ob-
tained from IRBP 201–216-primed/EHC 44–59-immunized animals 
responded comparably to both the peptides (IRBP 201–216: 3.4-
fold, p = 0.0005; EHC 44–59: 3.6-fold, p = 0.0001; Figure 6B, right 
panel), indicating that their responses were amplified in response to 
EHC 44–59-immunization. The data suggest that IRBP-sensitized T 
cells can expand to a significant proportion in response to EHC 44–
59, but the lack of EAU induction in IRBP-primed/EHC-immunized 
animals raises a question whether EHC 44–59 can behave as a dis-
ease-suppressing natural APL.
3.7. Altered EHC 44–59 can induce uveoretinitis
To address the possibility that EHC 44–59 can act as an APL, 
we chose to alter the peptide sequence by substituting the residues 
within the core region of EHC 44–59, thereby increasing the iden-
tity with IRBP 201–216. As indicated in Figure 7A, the region span-
ning amino acids 45 to 55 contains putative MHC- and TCR-contact 
residues similar to those in IRBP 201–216. This region of EHC 44–
59 is also identical to the same region in IRBP 201–216, except that 
alanine (Ala) occurs at positions 49 and 52, corresponding to posi-
tions 206 and 209 in IRBP 201–216, which contain valine and thre-
onine, respectively. We targeted these residues to generate APLs. In 
the first APL (EHC 44–59AP1), Ala at position 49 was substituted 
with valine (Val); in the second (EHC 44–59AP2), Ala at position 52 
was substituted with threonine (Thr); and in the third (EHC 44–
59AP3), Ala at both positions 49 and 52 were substituted with Val 
and Thr, respectively (Figure 7A).
We verified the disease-inducing abilities of APLs by immuniz-
ing groups of mice (n  =  10) and euthanizing animals after three 
weeks to enucleate the eyes for histological evaluation of EAU. Fig-
ure 7B [top panels (i), (ii) and (iii)] shows that the mice immunized 
with EHC 44–59AP1 had inflammatory foci in the sclera, cornea, cili-
ary body and posterior chamber (3/10 = 30%), and none of the mice 
immunized with EHC 44–59AP2 or EHC 44–59AP3 had lesions (Fig-
ure  7B, bottom panels). We next examined whether these differ-
ential effects of APLs may be due to variations, if any, in the gen-
eration of IRBP-reactive T cells in response to APLs. As expected, 
LNC from mice immunized with IRBP 201–216 responded to IRBP 
201–216 with a 3.5-fold enhancement relative to the medium con-
trols, but responses to APLs varied (Figure 7C, upper left panel) in 
that the response to EHC 44–59AP1 was relatively higher (3.3-fold) 
than responses to the other two APLs. Likewise, by testing the T 
cell responses in mice immunized with APLs, we noted that LNC 
from mice immunized with EHC 44–59AP1 responded well to both 
the immunizing peptide and IRBP 201–216 (Figure 7C, upper right 
panel). Such responses were low in animals immunized with EHC 
44–59AP2 or EHC 44–59AP3 (Figure 7C, bottom panels). Similar dif-
ferences also were noted with the cytokine analysis, where LNC cul-
tures derived from mice immunized with EHC 44–59AP1 contained a 
higher proportion of IFN-γ-producing Th1 cells than cultures from 
mice immunized with EHC 44–59AP2 (p = 0.045) or EHC 44–59AP3 
(p  =  0.023; Figure  7D). Furthermore, by evaluating the IAk-bind-
ing affinities of APLs (Figure 8), we noted that EHC 44–59AP1 binds 
much more strongly to IAk molecules (IC50: 4.14 ± 0.28 μM) than do 
EHC 44–59AP2 (IC50: 9.35 ± 0.55 μM; p = 0.001) and EHC 44–59AP3 
(IC50: 7.48 ± 0.38 μM; p = 0.002). This may be the reason EHC 44–
59AP1 has greater immunogenicity and disease-inducing ability than 
the others. The fact that EHC 44–59 failed to induce EAU on its own 
and one of its APLs (EHC 44–59AP1) induced EAU by preferentially 
expanding IFN-γ-producing IRBP-reactive T cells further supported 
the proposal that EHC 44–59 may act as a naturally occurring APL.
4. Discussion
We report here identification of a mimicry epitope from E. canis 
for IRBP 201–216, which is recognized as one of the candidate ocular 
antigens in EAU pathogenesis ( Silver et al., 1995; Namba et al., 1998; 
Figure  6.  EHC 44–59 prevents development of uveoretinitis induced by 
IRBP 201–216. A. Histological EAU. Groups of mice were immunized with 
suboptimal doses of IRBP 201–216 (10 μg/mouse) seven days prior to im-
munization with or without EHC 44–59 or RNase 43–56 (100 μg/mouse) in 
CFA, and PT (500 ng/mouse) was administered on day 0 and day 2 after the 
first immunization. At termination on day 21, eyes were collected for histo-
logical evaluation of inflammation. Note scleral and posterior chamber lym-
phocytic infiltrates in animals immunized with the suboptimal dose of IRBP 
201–216 [(i) and (ii)]; normal sclera and ciliary body in animals primed with 
IRBP 201–216 and later immunized later with EHC 44–59 (iii); and presence 
of infiltrates in the corneal–scleral junction in animals primed with IRBP 
201–216 and subsequently immunized with control peptide (RNase 43–56) 
(iv). Original magnification, × 40 (bar = 20 μm). Representative data from 
three individual experiments, each involving 4 to 5 mice, are shown. B. T cell 
proliferation. LNC harvested from the above groups were stimulated with 
the indicated peptides for two days followed by pulsing with 3[H] thymidine. 
Proliferative responses were measured 16 h later as cpm. RNase 43–56, con-
trol. Mean ± SEM values derived from representative experiment from three 
individual experiments, each involving 4 to 5 mice, are shown.
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Cortes et al., 2008;  Agarwal et al., 2012). Unexpectedly, instead of 
functioning as a disease-inducing antigen, the mimicry epitope (EHC 
44–59) prevented the disease induced with IRBP 201–216. We pro-
vide four lines of evidence to support this finding: 1) EHC 44–59 and 
IRBP 201–216 contain identical discontinuous stretches of nine res-
idues in which the putative MHC- and TCR-contact residues are lo-
calized (Figure 1); 2) T cell responses induced by EHC 44–59 cross-
react with IRBP 201–216, and the antigen-sensitized T cells produce 
predominantly Th1 and Th17 cytokines that promote organ-spe-
cific autoimmunity, including EAU (Figure 4; Luger et al., 2008; Yo-
shimura et al., 2009); 3) the mimicry epitope prevented the develop-
ment of EAU in animals previously primed with IRBP 201–216, and 
such an alteration in the disease phenotype was not due to the ab-
sence of IRBP-reactive T cells ( Figure 6); and 4) finally, one of the al-
tered peptides of the mimicry epitope (EHC 44–59AP1) that shows a 
resemblance to IRBP 201–216 induced EAU through the production 
of IFN-γ-producing, IRBP-reactive T cells (Figure 7).
Uveitis is a sight-threatening disease that accounts for approxi-
mately 10% of severe vision loss (Agarwal et al., 2012), and autoim-
mune responses have been suspected in the disease mediation (Wild-
ner and Diedrichs-Mohring, 2004; Levy et al., 2011; Agarwal et al., 
2012). To delineate the immune events of uveitis, various rodent 
models of EAU have been developed, and the disease is induced by 
immunizing the animals with ocular antigens or their peptide frag-
ments (Caspi et al., 1988; Shinohara et al., 1990; Namba et al., 1998; 
Caspi, 2003; Agarwal et al., 2012). Although it is difficult to recapit-
ulate all events in animal models, histologic features of EAU resem-
ble those of uveitis in humans. Thus, EAU models are commonly em-
ployed to study the immune pathogenesis of sight-threatening ocular 
diseases such as sympathetic ophthalmia, Behcet’s disease, birdshot 
Figure 7. EHC 44–59AP1 – but not EHC 44–59AP2 and EHC 44–59AP3 – induces EAU. A. Comparison of sequences between IRBP 201–216 and altered EHC 
peptides. Three altered peptides were generated for EHC 44–59, such that Ala at positions 49 and 52 was substituted with Val and Thr, respectively, in the 
first (EHC 44–59AP1) and second peptides (EHC 44–59AP2), and both substitutions were made in the third peptide (EHC 44–59AP3). Identical residues are un-
derlined, and the substituted residues are overlined. B. Histological EAU. Groups of mice were immunized with the indicated peptides (50 μg/mouse) in CFA, 
and PT (500 ng/mouse) was administered intraperitoneally on days 0 and 2 postimmunization. At termination on day 21, eyes were enucleated for histolog-
ical evaluation of inflammation. Note lymphocytic infiltrates at corneal–scleral junctions (i), iris (ii), and posterior chamber (iii) in animals immunized with 
EHC 44–59AP1 (arrows), as opposed to normal sections in animals immunized with EHC 44–59AP2 or EHC 44–59AP3 (bottom panel). Original magnification, 
× 40 (bar = 20 μm). Representative data from two individual experiments, each involving five mice, are shown. C. T cell proliferation. LNC generated from the 
above groups were stimulated with the indicated peptides for two days, and, after pulsing with 3[H] thymidine, proliferative responses were measured as cpm. 
Data sets from two experiments, each involving 5 to 8 mice, are shown. D. Intracellular cytokine staining. LNC were first stimulated with the indicated pep-
tides for two days in growth medium, and IL-2 was then supplemented. On day 5, viable cells were stimulated with PMA/ionomycin in the presence of GolgiS-
top for five hours, and, after staining with anti-CD4 and 7-AAD, cells were fixed and permeabilized to stain with cytokine antibodies. Cells were then acquired 
by flow cytometry, and the percent cytokine+ cells were enumerated in the live (7-AAD−) CD4 subset. Mean ± SEM values derived from two individual experi-
ments, each involving 5 mice, are shown.
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retinochoroidopathy and Vogt–Koyanagi–Harada syndrome (Agarwal 
et al., 2012). While rats are susceptible to EAU induced with both sol-
uble antigen (also called arrestin) and IRBP, mice are susceptible to 
only IRBP, and various uveitogenic epitopes of IRBP have been iden-
tified (Caspi et al., 1988; Caspi, 2003; Cortes et al., 2008; Agarwal et 
al., 2012). One such epitope is IRBP 201–216, which is expected to 
induce EAU with a relatively higher degree of severity in B10.A mice 
than in A/J mice (Caspi, 2003), yet both strains possess a similar 
MHC class II/IAk allele. However, in our hands, IRBP 201–216, in ad-
dition to being less immunogenic, induced EAU with less severity in 
B10.A mice than in A/J mice (data not shown), leading us to use A/J 
mice to test the uveitogenicity of mimicry epitopes in our studies.
Generally, exposure to mimicry sequences is expected to lead 
to induction of pathogenic cross-reactive T cells or autoantibodies 
(Singh et al., 1990; Shinohara et al., 1991; Rose, 2001, Fujinami et 
al., 2006; Massilamany et al., 2011b). An exception to this paradigm 
is the possibility that cross-reactive immune responses may not 
lead to disease, as shown with a mimic from Haemophilus influen-
zae for myelin proteolipid protein 139–151 (Carrizosa et al., 1998). 
Alternatively, although less commonly reported, mimicry epitopes 
can act as APLs by suppressing diseases like experimental autoim-
mune encephalomyelitis induced with a cognate epitope, myelin ba-
sic protein 85–99 (Ruiz et al., 1999; Steinman et al., 2005; Mavera-
kis et al., 2010). Our data with EHC 44–59 agree with the concept 
that microbial mimics can act as APLs but provide new insights as 
to their underlying mechanisms.
APLs are believed to act by ablating antigen-specific T cell re-
sponses or by deviating cytokine responses from a Th1 (disease-pro-
moting) to a Th2 (disease-suppressing) phenotype and/or promoting 
the generation of regulatory T cells (Paas-Rozner et al., 2001; Alleva 
et al., 2002; Aruna et al., 2006). In our studies with EHC 44–59, while 
generation of antigen (IRBP 201–216)-specific T cell responses was 
not altered, the EHC-responsive T cells produced both Th1 and Th17 
cytokines similar to those produced by IRBP-reactive T cells. On the 
contrary, production of Th2 cytokines contributed by IL-4 and IL-10 
was not elevated. We further ruled out a possibility that differences, 
if any, in the frequencies of IRBP-reactive T cells could account for 
lack of disease induced with EHC 44–59 by immunizing the animals 
primed previously with IRBP 201–216 (Figure  6). In this setting, 
we noted that T cells specific to both antigens were present, leading 
to the conclusion that EHC 44–59 did not selectively deplete IRBP-
specific cells. However, recent studies indicate that APLs can inhibit 
T cell activation by affecting phosphorylation of key T cell signaling 
molecules, such as CD3ζ, CD3ε, Zap-70, src kinases, p56lck and p59fyn 
(Madrenas et al., 1995; Sloan-Lancaster and Allen, 1996). But we did 
not investigate these possibilities in our studies.
As additional evidence for a proposal that EHC 44–59 can act as 
an APL, we altered the peptide sequence to more closely resemble 
the cognate peptide IRBP 210–216 by changing two Ala residues in-
dividually or together. We noted that one peptide (EHC 44–59AP1) 
that contained Val in place of Ala at position 49 was able to induce 
EAU. EHC 44–59AP3 bearing two substitutions at positions 49 and 
52 was expected to induce EAU, but this was not the case. Evidently, 
the amount of IRBP-reactive T cells produced in response to this pep-
tide was also low (Figure 7C, bottom right panel). Further, by cyto-
kine analysis, we noted that the frequencies of IFN-γ-producing cells 
were elevated only with the disease-inducing peptide EHC 44–59AP1 
(Figure 7D). Numerous studies indicate that EAU induction requires 
the mediation of both Th1 and Th17 cells (Xu et al., 1997, 2004; Peng 
et al., 2007;  Luger et al., 2008), but the disease can be induced in 
C57Bl/6 mice deficient for IFN-γ or IL-17 with deviant or altered dis-
ease phenotypes (Caspi et al., 1994; Jones et al., 1997; Luger et al., 
2008; Yoshimura et al., 2008). Furthermore, IFN-γ appears to medi-
ate multiple roles (disease-aggravating or disease-protective) in EAU 
pathogenesis (Jones et al., 1997; Xu et al., 2004; Tang et al., 2007). 
Whether such differential effects are dose dependent is not known. 
Since EHC 44–59AP1 induced higher frequencies of IFN-γ-producing 
IRBP-reactive T cells than two other altered peptides (EHC 44–59AP2 
and EHC 44–59AP3), our data suggest that IFN-γ-producing cells may 
have led to the disease mediation.
In summary, we have provided evidence that a mimicry epitope 
derived from E. canis can act as a naturally occurring APL by sup-
pressing the disease induced with IRBP 201–216 without altering 
IRBP-specific T cell responses. To induce cross-reactive immune re-
sponses for microbes carrying mimicry epitopes, humans need not 
be natural hosts. Conversely, the natural pathogens of humans car-
rying the mimicry epitopes can induce inflammation by generating 
cross-reactive immune responses, but such responses can be detri-
mental to the survival of parasites. It may be that, evolutionarily, 
coexistence of parasites with hosts may promote acquisition of the 
host’s genetic material, and introduction of mutations under selec-
tion pressure may favor attenuation of the host’s immune response, 
leading to their survival.
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